NCT02228213 - Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

June 30, 2017

Conditions

Secondary Progressive Multiple Sclerosis

Interventions

BIOLOGICAL

MIS416

Intravenous administration weekly for 52 weeks

DRUG

Saline

Intravenous administration weekly for 52 weeks

Trial Locations (7)

Optimal Clinical Trials, Auckland

Nucleus Network - Centre for Clinical Studies, Melbourne

The Wesley-St. Andrew's Research Institute, Brisbane

PARC Clinical Research, Adelaide

Neurodegenerative Disorders Research, West Perth

Western Australian Neuroscience Research Institute, Perth

P3 Research, Wellington